-
Something wrong with this record ?
The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
C. Abdelnour, D. Ferreira, K. Oppedal, L. Cavallin, O. Bousiges, LO. Wahlund, J. Hort, Z. Nedelska, A. Padovani, A. Pilotto, L. Bonanni, MG. Kramberger, M. Boada, E. Westman, J. Pagonabarraga, J. Kulisevsky, F. Blanc, D. Aarsland
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2012
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012 to 2020
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
- MeSH
- Alzheimer Disease * diagnostic imaging MeSH
- Amyloid beta-Peptides MeSH
- Atrophy MeSH
- Biomarkers MeSH
- Lewy Body Disease * diagnostic imaging MeSH
- Humans MeSH
- Brain diagnostic imaging MeSH
- Peptide Fragments MeSH
- tau Proteins MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Alzheimer's disease (AD)-related pathology is frequently found in patients with dementia with Lewy bodies (DLB). However, it is unknown how amyloid-β and tau-related pathologies influence neurodegeneration in DLB. Understanding the mechanisms underlying brain atrophy in DLB can improve our knowledge about disease progression, differential diagnosis, drug development and testing of anti-amyloid and anti-tau therapies in DLB. OBJECTIVES: We aimed at investigating the combined effect of CSF amyloid-β42, phosphorylated tau and total tau on regional brain atrophy in DLB in the European DLB (E-DLB) cohort. METHODS: 86 probable DLB patients from the E-DLB cohort with CSF and MRI data were included. Random forest was used to analyze the association of CSF biomarkers (predictors) with visual rating scales for medial temporal lobe atrophy (MTA), posterior atrophy (PA) and global cortical atrophy scale-frontal subscale (GCA-F) (outcomes), including age, sex, education and disease duration as extra predictors. RESULTS: DLB patients with abnormal MTA scores had abnormal CSF Aβ42, shorter disease duration and older age. DLB patients with abnormal PA scores had abnormal levels of CSF Aβ42 and p-tau, older age, lower education and shorter disease duration. Abnormal GCA-F scores were associated with lower education, male sex, and older age, but not with any AD-related CSF biomarker. CONCLUSIONS: This study shows preliminary data on the potential combined effect of amyloid-β and tau-related pathologies on the integrity of posterior brain cortices in DLB patients, whereas only amyloid-β seems to be related to MTA. Future availability of α-synuclein biomarkers will help us to understand the effect of α-synuclein and AD-related pathologies on brain integrity in DLB.
Centre for Age Related Medicine Stavanger University Hospital Stavanger Norway
Department of Electrical Engineering and Computer Science University of Stavanger Stavanger Norway
Department of Medicine of the Universitat Autònoma de Barcelona Barcelona Spain
Department of Radiology Stavanger University Hospital Stavanger Norway
Hôpitaux Universitaire de Strasbourg CMRR équipe IMIS Neurocrypto Strasbourg France
Institute of Psychiatry Psychology and Neuroscience King's College London London UK
International Clinical Research Centre Brno Czech Republic
Neurology Unit Department of Clinical and Experimental Sciences University of Brescia Brescia Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020838
- 003
- CZ-PrNML
- 005
- 20210830102454.0
- 007
- ta
- 008
- 210728s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.nicl.2020.102333 $2 doi
- 035 __
- $a (PubMed)32674011
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Abdelnour, Carla $u Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain; Department of Medicine of the Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: cabdelnour@fundacioace.org
- 245 14
- $a The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies / $c C. Abdelnour, D. Ferreira, K. Oppedal, L. Cavallin, O. Bousiges, LO. Wahlund, J. Hort, Z. Nedelska, A. Padovani, A. Pilotto, L. Bonanni, MG. Kramberger, M. Boada, E. Westman, J. Pagonabarraga, J. Kulisevsky, F. Blanc, D. Aarsland
- 520 9_
- $a BACKGROUND: Alzheimer's disease (AD)-related pathology is frequently found in patients with dementia with Lewy bodies (DLB). However, it is unknown how amyloid-β and tau-related pathologies influence neurodegeneration in DLB. Understanding the mechanisms underlying brain atrophy in DLB can improve our knowledge about disease progression, differential diagnosis, drug development and testing of anti-amyloid and anti-tau therapies in DLB. OBJECTIVES: We aimed at investigating the combined effect of CSF amyloid-β42, phosphorylated tau and total tau on regional brain atrophy in DLB in the European DLB (E-DLB) cohort. METHODS: 86 probable DLB patients from the E-DLB cohort with CSF and MRI data were included. Random forest was used to analyze the association of CSF biomarkers (predictors) with visual rating scales for medial temporal lobe atrophy (MTA), posterior atrophy (PA) and global cortical atrophy scale-frontal subscale (GCA-F) (outcomes), including age, sex, education and disease duration as extra predictors. RESULTS: DLB patients with abnormal MTA scores had abnormal CSF Aβ42, shorter disease duration and older age. DLB patients with abnormal PA scores had abnormal levels of CSF Aβ42 and p-tau, older age, lower education and shorter disease duration. Abnormal GCA-F scores were associated with lower education, male sex, and older age, but not with any AD-related CSF biomarker. CONCLUSIONS: This study shows preliminary data on the potential combined effect of amyloid-β and tau-related pathologies on the integrity of posterior brain cortices in DLB patients, whereas only amyloid-β seems to be related to MTA. Future availability of α-synuclein biomarkers will help us to understand the effect of α-synuclein and AD-related pathologies on brain integrity in DLB.
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a Alzheimerova nemoc $x diagnostické zobrazování $7 D000544
- 650 _2
- $a amyloidní beta-protein $7 D016229
- 650 _2
- $a atrofie $7 D001284
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a mozek $x diagnostické zobrazování $7 D001921
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a demence s Lewyho tělísky $x diagnostické zobrazování $7 D020961
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a peptidové fragmenty $7 D010446
- 650 _2
- $a proteiny tau $7 D016875
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ferreira, Daniel $u Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Oppedal, Ketil $u Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway; Department of Radiology, Stavanger University Hospital, Stavanger, Norway; Department of Electrical Engineering and Computer Science, University of Stavanger, Stavanger, Norway
- 700 1_
- $a Cavallin, Lena $u Department of Neuroscience, Karolinska Institutet and Department of Radiology Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Bousiges, Olivier $u Hôpitaux Universitaire de Strasbourg, Laboratoire de Biochimie et Biologie Moléculaire, et CNRS, Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR7364, Strasbourg, France
- 700 1_
- $a Wahlund, Lars Olof $u Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Hort, Jakub $u Department of Neurology, Charles University, 2nd Medical Faculty and Motol University Hospital, Prague, Czech Republic; International Clinical Research Centre, Brno, Czech Republic
- 700 1_
- $a Nedelska, Zuzana $u Department of Neurology, Charles University, 2nd Medical Faculty and Motol University Hospital, Prague, Czech Republic; International Clinical Research Centre, Brno, Czech Republic
- 700 1_
- $a Padovani, Alessandro $u Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- 700 1_
- $a Pilotto, Andrea $u Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- 700 1_
- $a Bonanni, Laura $u Department of Neuroscience Imaging and Clinical Sciences and CESI, University G d'Annunzio of Chieti-Pescara, Chieti, Italy
- 700 1_
- $a Kramberger, Milica G $u Department of Neurology, University Medical Centre Ljubljana, Medical faculty, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Boada, Mercè $u Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya-Barcelona, Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- 700 1_
- $a Westman, Eric $u Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- 700 1_
- $a Pagonabarraga, Javier $u Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau. Biomedical Research Institute (IIB-Sant Pau), Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- 700 1_
- $a Kulisevsky, Jaime $u Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau. Biomedical Research Institute (IIB-Sant Pau), Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
- 700 1_
- $a Blanc, Frédéric $u Hôpitaux Universitaire de Strasbourg, CMRR (Centre Mémoire de Ressource et de Recherche), Hôpital de jour, pôle de Gériatrie, et CNRS, laboratoire ICube UMR 7357 et FMTS (Fédération de MédecineTranslationnelle de Strasbourg), équipe IMIS/Neurocrypto, Strasbourg, France
- 700 1_
- $a Aarsland, Dag $u Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- 773 0_
- $w MED00188130 $t NeuroImage. Clinical $x 2213-1582 $g Roč. 27, č. - (2020), s. 102333
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32674011 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102455 $b ABA008
- 999 __
- $a ok $b bmc $g 1691428 $s 1141284
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 27 $c - $d 102333 $e 20200702 $i 2213-1582 $m NeuroImage. Clinical $n Neuroimage Clin $x MED00188130
- LZP __
- $a Pubmed-20210728
